Statin + ezetimibe
Statin + ezetimibe has been studied in 21 papers since 2021: 1 trial and 14 observational studies in people, 6 reviews; 16 in the past year. The newest paper, Oct 27, 2026: “Role of statin/ezetimibe fixed-dose combination in lipid risk management in the cardiovascular disease continuum”.
61 new papers in 30 daysSee all 179
“moderate-intensity + ezetimibe vs placebo RR 0.93 (95% CrI 0.62–1.4).”
1 of its findings points the other way.
- 10 independent labs in 7 countries
- 1 finding against
- 6 trials, none about aging, 1 with no results posted
- Funders: Inha University and 4 more
- 4 of 20 findings with company ties
- Human trial1
- Humans14
Studies in people
2 studies gave statin + ezetimibe to people and measured what changed.
no change: Has no effect on cancer incidenceRR 0.93 (95% CrI 0.62–1.4)
Review of trials219,006 people pooledBoth~4 years
Patient cohorts; General population
ESC Congress 2026 abstract, Oct 26, 2026
no change: Has no effect on cardiovascular death, major cardiovascular events, or nonfatal stroke10.6% vs 12.3%; HR: 0.87; 95% CI: 0.54-1.42; P = 0.581
down: Decreases intolerance-related drug discontinuation or dose reduction2.3% vs 7.2%; P = 0.010
Randomized trial3,780 people≥75 years3-year
Older adults; The oldest old; atherosclerotic cardiovascular disease
Journal of the American College of Cardiology, Apr 6, 2023
What did studies of Statin + ezetimibe find?
12Studies of Statin + ezetimibe measured 12 outcomes; the most studied are LDL-C (3 studies), LDL cholesterol (2) and mortality (2).
LDL-C
downin humans3
3 studies
LDL-C
downin humans3
Statin + ezetimibe decreases LDL-C in humans (versus statin monotherapy in ACS patients) (11.9 mg/dL (10.9–13.0)).
“Mean differences (95% Credible Interval) were 11.9 mg/dL (10.9–13.0) for ezetimibe + statin (E+S)”
Human trialversus statin monotherapy in ACS patients
ESC Congress 2026 abstract
Statin + ezetimibe is linked with lower LDL-C in humans (atherosclerotic cardiovascular disease) (-39.6%, p < 0.001).
“The mean low-density lipoprotein cholesterol (LDL-C) level significantly decreased from 129.4 ± 18.7 mg/dL at baseline to 78.2 ± 16.4 mg/dL at six months (p < 0.001), representing a 39.6% reduction.”
Humansatherosclerotic cardiovascular diseasesix monthsn = 221
Cureus
Statin + ezetimibe decreases LDL-C in humans (atherosclerotic vascular disease).
“Whereby, ezetimibe plus statins may reduce LDL-C more strongly than statins alone.”
Reviewatherosclerotic vascular disease
The safety and efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases
Aging and disease
LDL cholesterol
downin humans2
2 studies
LDL cholesterol
downin humans2
Statin + ezetimibe is linked with lower LDL cholesterol in humans after ST-elevation myocardial infarction; lipid-lowering regimens varied during follow-up (Median 3.66 mmol/l at baseline versus 1.32 mmol/l at follow-up).
“optimal lipid-lowering therapy reduces LDL-C”
Humansafter ST-elevation myocardial infarction; lipid-lowering regimens varied during follow-up5 yearsn = 12
ESC Congress 2026 abstract
Statin + ezetimibe decreases LDL cholesterol in humans (Compared with statin titration alone).
“combination therapy with statin and ezetimibe allows for a more effective LDL-C reduction compared with the statin titration alone”
ReviewCompared with statin titration alone
Giornale italiano di cardiologia (2006)
Mortality
downin humans2HR 0.85–0.92
2 studies
Mortality
downin humans2HR 0.85–0.92
Statin + ezetimibe is linked with lower mortality in humans (HR 0.85).
“cancer-related mortality (HR, 0.85; P<0.001) compared with statin monotherapy”
Humansn = 669,036
Endocrinology and metabolism (Seoul, Korea)
Statin + ezetimibe is linked with lower mortality in patients with type 2 diabetes receiving statin therapy (HR 0.92, P=0.033).
“all-cause mortality (HR 0.92; P=0.033) compared to statin monotherapy”
Humansin patients with type 2 diabetes receiving statin therapy>3 monthsn = 89,866
ADA Scientific Sessions 2025 abstract
Cardiovascular events
downin humans1
1 study
Cardiovascular events
downin humans1
Statin + ezetimibe decreases cardiovascular events in humans (Early initiation of combination therapy).
“early initiation of combination therapy increases the likelihood of achieving LDL-C goals and of reducing cardiovascular events.”
ReviewEarly initiation of combination therapy
Giornale italiano di cardiologia (2006)
LDL cholesterol target attainment
upin humans1
1 study
LDL cholesterol target attainment
upin humans1
Statin + ezetimibe increases LDL cholesterol target attainment in humans (compared with statin intensification alone).
“Evidence indicates greater efficacy in achieving LDL-C targets compared with statin intensification alone, along with favorable treatment adherence.”
Reviewcompared with statin intensification alone
From guidelines: cardiovascular risk stratification and therapeutic targets
Giornale italiano di cardiologia (2006)
Low-density lipoprotein cholesterol
downin humans1
1 study
Low-density lipoprotein cholesterol
downin humans1
Statin + ezetimibe is linked with lower low-density lipoprotein cholesterol in statin-naive ACS patients with admission LDL-C >110 mg/dL (47 [39–62] vs. 65 [55–86] mg/dL).
“Patients on combination therapy achieved significantly lower follow-up LDL-C levels (47 [39–62] vs. 65 [55–86] mg/dL; p < 0.001)”
Humansin statin-naive ACS patients with admission LDL-C >110 mg/dL3 monthsn = 211
ESC Congress 2026 abstract
Cancer incidence
no changein humans1RR 0.93
1 study
Cancer incidence
no changein humans1RR 0.93
Statin + ezetimibe showed no clear effect on cancer incidence in humans (RR 0.93 (95% CrI 0.62–1.4)).
“moderate-intensity + ezetimibe vs placebo RR 0.93 (95% CrI 0.62–1.4).”
Human trialn = 219,006
ESC Congress 2026 abstract
Revision rotator cuff repair
no changein humans1RR 0.853
1 study
Revision rotator cuff repair
no changein humans1RR 0.853
Statin + ezetimibe was not clearly linked with revision rotator cuff repair in humans Following arthroscopic rotator cuff repair; compared with patients without hyperlipidemia (5.4% vs. 6.4%; RR 0.853).
“Compared with patients without HLD, statin-ezetimibe therapy demonstrated similar rates of revision RCR (5.4% vs. 6.4%; RR 0.853; p = 0.358)”
HumansFollowing arthroscopic rotator cuff repair; compared with patients without hyperlipidemiarotator cuff5 yearsn = 1,066
Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences
Cancer-related mortality
downin humans1HR 0.8
1 study
Cancer-related mortality
downin humans1HR 0.8
Statin + ezetimibe is linked with lower cancer-related mortality in patients with type 2 diabetes receiving statin therapy (HR 0.80, P<0.001).
“cancer-related mortality (HR 0.80; P<0.001)”
Humansin patients with type 2 diabetes receiving statin therapy>3 monthsn = 89,866
ADA Scientific Sessions 2025 abstract
Intolerance-related drug discontinuation or dose reduction
downin humans1
1 study
Intolerance-related drug discontinuation or dose reduction
downin humans1
Statin + ezetimibe decreases intolerance-related drug discontinuation or dose reduction in humans (atherosclerotic cardiovascular disease) (2.3% vs 7.2%; P = 0.010).
“Moderate-intensity statin with ezetimibe combination therapy was associated with lower rates of intolerance-related drug discontinuation or dose reduction among patients aged ≥75 years”
Human trialatherosclerotic cardiovascular disease
Journal of the American College of Cardiology
Cardiovascular death, major cardiovascular events, or nonfatal stroke
no changein humans1HR 0.87
1 study
Cardiovascular death, major cardiovascular events, or nonfatal stroke
no changein humans1HR 0.87
Statin + ezetimibe showed no clear effect on cardiovascular death, major cardiovascular events, or nonfatal stroke in humans (atherosclerotic cardiovascular disease) (10.6% vs 12.3%; HR: 0.87; 95% CI: 0.54-1.42; P = 0.581).
“The rates of the primary endpoint were not different between the moderate-intensity statin with ezetimibe combination therapy group and the high-intensity statin monotherapy group among patients aged ≥75 years”
Human trialatherosclerotic cardiovascular disease3-year
Journal of the American College of Cardiology
All 12Fewer
What is Statin + ezetimibe linked with?
7Studies link Statin + ezetimibe with 7 measures, most often cancer (2 studies), microvascular function (1) and revision rotator cuff repair (1).
Cancer
downin humans2HR 0.88–0.89
2 studies
Cancer
downin humans2HR 0.88–0.89
Statin + ezetimibe is linked with a lower risk of cancer in humans (HR 0.89).
“ezetimibe-statin combination therapy was associated with a significantly lower risk of cancer (hazard ratio [HR], 0.89; P<0.001)”
Humansn = 669,036
Endocrinology and metabolism (Seoul, Korea)
Statin + ezetimibe is linked with a lower risk of cancer in patients with type 2 diabetes receiving statin therapy (HR 0.88, P<0.001).
“the combination of ezetimibe and statin was associated with a significantly lower risk of incident cancer (HR 0.88; P<0.001)”
Humansin patients with type 2 diabetes receiving statin therapy>3 monthsn = 89,866
ADA Scientific Sessions 2025 abstract
Microvascular function
upin humans1
1 study
Microvascular function
upin humans1
Statin + ezetimibe is associated with microvascular function in humans after ST-elevation myocardial infarction; lipid-lowering regimens varied during follow-up.
“optimal lipid-lowering therapy reduces LDL-C and is associated with improved microvascular dysfunction assessed by retinal vessel analysis during long term follow up.”
Humansafter ST-elevation myocardial infarction; lipid-lowering regimens varied during follow-upretinal blood vessel5 yearsn = 12
ESC Congress 2026 abstract
Revision rotator cuff repair
downin humans1RR 0.697
1 study
Revision rotator cuff repair
downin humans1RR 0.697
Statin + ezetimibe is associated with revision rotator cuff repair in humans (5.6% vs. 8.0%; RR 0.697).
“Compared with statin monotherapy, statin-ezetimibe therapy was associated with lower rates of revision RCR (5.6% vs. 8.0%; RR 0.697; p = 0.023)”
HumansHyperlipidemia following arthroscopic rotator cuff repair; compared with statin monotherapyrotator cuff5 yearsn = 1,114
Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences
Myalgia
upin humans1
1 study
Myalgia
upin humans1
Statin + ezetimibe is associated with myalgia in humans (atherosclerotic cardiovascular disease) (3.2% (7/221)).
“Adverse events were infrequent: myalgia occurred in seven patients (3.2%), elevated liver enzymes in five patients (2.3%), and creatine kinase increase in four patients (1.8%), with no cases of rhabdomyolysis.”
Humansatherosclerotic cardiovascular diseasesix monthsn = 221
Cureus
Major adverse cardiovascular events
upin humans1
1 study
Major adverse cardiovascular events
upin humans1
Statin + ezetimibe is associated with major adverse cardiovascular events in humans (atherosclerotic cardiovascular disease) (5.0% (11/221)).
“A total of 11 patients (5.0%) experienced major adverse cardiovascular events (MACE) during follow-up.”
Humansatherosclerotic cardiovascular diseasesix monthsn = 221
Cureus
Lymphoid and hematopoietic cancers
downin humans1HR 0.66
1 study
Lymphoid and hematopoietic cancers
downin humans1HR 0.66
Statin + ezetimibe is linked with a lower risk of lymphoid and hematopoietic cancers in patients with type 2 diabetes receiving statin therapy (HR 0.66, P=0.017).
“lymphoid/hematopoietic cancers (HR 0.66; P=0.017)”
Humansin patients with type 2 diabetes receiving statin therapy>3 monthsn = 89,866
ADA Scientific Sessions 2025 abstract
Liver cancer
downin humans1HR 0.75
1 study
Liver cancer
downin humans1HR 0.75
Statin + ezetimibe is linked with a lower risk of liver cancer in patients with type 2 diabetes receiving statin therapy (HR 0.75, P=0.007).
“Ezetimibe combination therapy also reduced the risk of specific cancer types, including liver (HR 0.75; P=0.007)”
Humansin patients with type 2 diabetes receiving statin therapy>3 monthsn = 89,866
ADA Scientific Sessions 2025 abstract
What acts on Statin + ezetimibe?
1Studies name 1 thing that act on Statin + ezetimibe, most often Guideline update (1 study).
Guideline update
upin humans1
1 study
Guideline update
upin humans1
guideline update is linked with higher statin + ezetimibe in humans following 2024 EACS guideline update (9% vs 19%).
“greater use of statin-ezetimibe combination therapy (9% vs 19%, p < 0.0001)”
Humansfollowing 2024 EACS guideline update
Nutrition, metabolism, and cardiovascular diseases : NMCD
Has Statin + ezetimibe been tested in people?
0 about aging, of 6Yes: 1 trial and 14 observational studies in people have been published, and 6 trials are registered.
In trials
Phase 4Results posted4 trials
Phase 4Results posted1 trial
Phase 4Results posted1 trial
Phase 4Results posted1 trial
Phase 3Completed1 trial
Phase 2Recruiting1 trial
Trial sponsors
Company2 trialsPhase 4852 people
Company1 trialPhase 2527 people
1 trialPhase 4151 people
1 trialPhase 4102 people
Chang Gung Medical Foundation, Taiwan
1 trialPhase 2300 people